Director Global Market Access and Pricing tolebrutinib

Job Title: Director Global Market Access and Pricing tolebrutinib

Location: Cambridge, MA

About the Job

Tolebrutinib, one of Sanofi’s priority assets and a key pillar of the Neurology Franchise, is the first brain-penetrant, bio-active Bruton’s tyrosine kinase inhibitor in multiple sclerosis (MS), with the broadest pivotal program ever, spanning the entire spectrum of MS. Supported by phase 3 results, tolebrutinib may change the practice of medicine in MS by offering a unique approach to controlling disability accumulation.   

The FDA has granted Breakthrough Therapy designation for tolebrutinib in nrSPMS. Regulatory filing is underway, with submission to the FDA and EMA completed earlier this year, and more to come over the next months. 

The PERSEUS phase 3 study in primary progressive MS (PPMS) patients is ongoing, with data expected in H2 2025. 

The Global Market Access & Pricing Director for tolebrutinib will be part of the Global Market Access and Pricing Neurology Team and contribute to the global pricing and access strategy of tolebrutinib across its MS indications, with focus on indication expansion to PPMS, as well as support the end-to-end execution of the strategy.  

This includes: 

• Contributing to the development of the payer value & pricing positioning for tolebrutinib, assessing the impact of the ph3 clinical trial outcomes in PPMS on launch prices & access 

• Driving the development of a compelling value story & messaging, integrating the PPMS trial results into tolebrutinib overall payer value story 

• Contributing to the preparation of the PPMS Go-to-file internal governance and scenario planning in partnership with the GPT and wave 1&2 countries 

• Providing end-to-end market access support to countries to drive excellence in pricing & access strategy execution 

Given the highly competitive MS market, as well as our ambition to change the treatment paradigm in MS with tolebrutinib, novel approaches and best in class methodologies will need to be fully leveraged to shape an optimal strategy in PPMS and realize tolebrutinib’s full pricing and access potential across its target indications. 

This is a h